News & Views
Research to Assess Gene Therapies Delivery
Nov 01 2017 Read 438 Times
A research collaboration is to assess the effectiveness of developing gene therapies using Avacta Group’s Affimer technology combined with FIT Biotech Oy’s gtGTU® platform. The very small, simply structured Affirmer proteins have ideal potential for delivering the DNA blueprint of therapeutic proteins into patient’s cells where it can be reproduced, although this natural process does need to achieve clinically relevant levels of the protein drug to be effective.
FIT Biotech’s gtGTU, a vector for delivering genes to patients, was developed to ensure the stable and prolonged production of therapeutic proteins by the patient’s cells, in a safe manner. It removes the requirement for frequent administration of biological therapeutics which are cleared from the body after a limited time.
Dr Alastair Smith, Avacta Group Chief Executive Officer said: “I am delighted that we are starting this collaboration with FIT Biotech. It is a very exciting prospect and the Group is keen to see the initial data from the pilot study which we anticipate will be in the first half of 2018.”
James Kuo, Chief Executive Officer of FIT Biotech added: “We very much look forward to working on this project together with Avacta (which) offers an exciting opportunity to take targeted therapies to a new level. This collaboration follows our strategy of bringing gtGTU to the gene therapy market through strong partnerships.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Choosing the Optimum Plasma Spectrochemistry Technique for Measuring Elemental Impurities in Pharmaceuticals - Monitoring Airborne Molecular Contamination in Indoo...
View all digital editions
Jun 27 2018 Tokyo, Japan
Jul 08 2018 Baltimore, MD, USA
Jul 29 2018 Chicago, IL, USA
Jul 29 2018 Washington DC, USA
Aug 05 2018 Baltimore, MD, USA